Renaissance Pharma

Renaissance Pharma was founded in 2023 by Executive Chairman Lee Morley and Chief Executive Officer Simon Ball. The company’s vision is to provide breakthrough therapeutic improvements for rare pediatric diseases. Initially, the company’s sole focus will be to accelerate the development of Hu14.18 for the treatment of newly diagnosed high-risk neuroblastoma. Renaissance, headquartered in Manchester, UK, is supported by a consortium of international healthcare investors led by the company’s leadership team.